R&D Systems Inc. Tocris Bioscience Boston Biochem

Pirlindole mesylate

Cat. No. 0724

Pirlindole mesylate C15H18N2.CH3SO3H [60762-57-4]

Price and Availability

For Pirlindole mesylate pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 2,3,3a,4,5,6-Hexahydro-8-methyl-1H-­pyrazino[3,2,1-j,k]carbazole mesylate

Biological Activity

A highly selective reversible inhibitor of monoamine oxidase type A.

Technical Data

M.Wt:
322.42
Formula:
C15H18N2.CH3SO3H
Solubility:
Soluble to 50 mM in water with gentle warming
Storage:
Store at RT
CAS No:
60762-57-4

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis is currently unavailable on-line. Please contact Customer Service
Safety Data Sheet: View Safety Data Sheet

References

Mashkovsky and Andreeva (1981) Pharmacological properties of 2,3,3α,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole hydrochloride (pirlindole), a new antidepressant. Arzneim.-Forsch.Drug Res. 31 75. PMID: 7194096.

Medvedev et al (1992) Efficacy of pirlindole, a highly selective reversible inhibitor of monoamine oxidase type A in the prevention of experimentally induced epiletic seizures. Drug Investigation. 4 501.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

5-HT Receptors 5-HT3 Receptors 5-HT-Related Adrenergic Receptors Adrenergic Related Compounds
Dopamine Receptors Dopaminergic-Related Monoamine Oxidase Oxygenases/Oxidases

Keywords: Pirlindole mesylate, supplier, MAO-A, inhibitors, MAO, Monoamine, Oxygenases, Oxidases

Quick Order

Find multiple products by catalog number

divider line

Neurobiology of Parkinson's Disease

Written by A. Schapira

Parkinson's Poster

'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.

divider line

Antidepressants - Current and Future Targets

Written by P. Skolnich et al

Antidepressants poster

'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.

divider line

New Product Guide

NPG

Highlights over 130 new products added in 2012. Request a copy or view PDF today.

divider line

New Products in this Area

NCX 466

Cyclooxygenase-inhibiting nitric oxide donor

Sign-up for new product e-alerts
divider line

20% Discount*

Potent, selective LRRK2 inhibitor

Potent LRRK2 inhibitor now available from Tocris Bioscience

Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.

* Terms & conditions